Hyperimmune intravenous immunoglobulin containing high titers of pandemic H1N1 hemagglutinin and neuraminidase antibodies provides dose-dependent protection against lethal virus challenge in SCID mice

Virology Journal

Volumn 11, Issue 1, 2014, Pages

  Hohenadl, Christine ^a   Wodal, Walter ^a   Kerschbaum, Astrid ^a   Fritz, Richard ^a   Howard, M Keith ^a   Farcet, Maria R ^a   Portsmouth, Daniel ^a   McVey, John K ^b   Baker, Donald A ^b   Ehrlich, Hartmut J ^a   Barrett, P Noel ^a   Kreil, Thomas R ^a  

^a BAXTER BIOSCIENCE   (Austria)

^b Global Quality Baxter BioScience   (United States)

Author keywords

H1N1; Hemagglutinin; Influenza; Intravenous immunoglobulin; IVIG; Neuraminidase; Neutralizing antibody; Passive transfer

Indexed keywords

HEMAGGLUTININ; HEMAGGLUTININ ANTIBODY; IMMUNOGLOBULIN; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS SIALIDASE; VIRUS SIALIDASE ANTIBODY;

2009 H1N1 INFLUENZA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; DRUG EFFICACY; HEMAGGLUTINATION INHIBITION; IMMUNOCOMPROMISED PATIENT; LETHALITY; MOUSE; NONHUMAN; PANDEMIC; PASSIVE IMMUNIZATION; PLASMA; SCID MOUSE; SURVIVAL;

MUS;

ANIMALS; ANTIBODIES, VIRAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; IMMUNOCOMPROMISED HOST; IMMUNOGLOBULINS, INTRAVENOUS; INFLUENZA A VIRUS, H1N1 SUBTYPE; MICE; MICE, SCID; NEURAMINIDASE; ORTHOMYXOVIRIDAE INFECTIONS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIRAL PROTEINS;

EID: 84899587290     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-11-70     Document Type: Article

References (24)

1. Hark back: passive immunotherapy for influenza and other serious infections. Luke TC, Casadevall A, Watowich SJ, Hoffman SL, Beigel JH, Burgess TH, Crit Care Med 2010 38 66 e73 20154602
2. Passive immunity in prevention and treatment of infectious diseases. Keller MA, Stiehm ER, Clin Microbiol Rev 2000 13 602 614 10.1128/CMR.13.4.602- 614.2000 11023960
3. World Health Organization, WHO Blood Regulators Network-Position Paper on collection and Use of Convalescent Plasma or Serum as an Element in Pandemic Influenza Planning Geneva, Switzerland: WHO 2009 1 4 http://www.who.int/ bloodproducts/brn/BRNPosition-ConvPlasma10July09.pdf
4. Convalescent transfusion for pandemic influenza: preparing blood banks for a new plasma product? Leider JP, Brunker PA, Ness PM, Transfusion 2010 50 1384 1398 20158681
5. New class of monoclonal antibodies against severe influenza: prophylactic and therapeutic efficacy in ferrets. Friesen RH, Koudstaal W, Koldijk MH, Weverling GJ, Brakenhoff JP, Lenting PJ, Stittelaar KJ, Osterhaus AD, Kompier R, Goudsmit J, PLoS One 2010 5 9106 10.1371/journal.pone.0009106 20161706
6. Prophylactic and therapeutic efficacy of avian antibodies against influenza virus H5N1 and H1N1 in mice. Nguyen HH, Tumpey TM, Park HJ, Byun YH, Tran LD, Nguyen VD, Kilgore PE, Czerkinsky C, Katz JM, Seong BL, Song JM, Kim YB, Do HT, Nguyen T, Nguyen CV, PLoS One 2010 5 10152 10.1371/journal.pone. 0010152 20405007
7. Prophylactic and therapeutic efficacy of a chimeric monoclonal antibody specific for H5 haemagglutinin against lethal H5N1 influenza. Prabhu N, Prabakaran M, Hongliang Q, He F, Ho HT, Qiang J, Goutama M, Lim AP, Hanson BJ, Kwang J, Antivir Ther 2009 14 911 921 10.3851/IMP1413 19918095
8. Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. Simmons CP, Bernasconi NL, Suguitan AL, Mills K, Ward JM, Chau NV, Hien TT, Sallusto F, Ha DQ, Farrar J, De J, Lanzavecchia A, Subbarao K, PLoS Med 2007 4 178 10.1371/journal.pmed.0040178 17535101 (Pubitemid 46842583)
9. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Hung IF, To KK, Lee CK, Lee KL, Chan K, Yan WW, Liu R, Watt CL, Chan WM, Lai KY, Koo CK, Buckley T, Chow FL, Wong KK, Chan HS, Ching CK, Tang BS, Lau CC, Li IW, Liu SH, Chan KH, Lin CK, Yuen KY, Clin Infect Dis 2011 52 447 456 10.1093/cid/ciq106 21248066
10. Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Hung IF, To KK, Lee CK, Lee KL, Yan WW, Chan K, Chan WM, Ngai CW, Law KI, Chow FL, Liu R, Lai KY, Lau CC, Liu SH, Chan KH, Lin CK, Yuen KY, Chest 2013 144 464 473 10.1378/chest.12-2907 23450336
11. Preparation of commercial quantities of a hyperimmune human intravenous immunoglobulin preparation against an emerging infectious disease: the example of pandemic H1N1 influenza. Kreil TR, Mc Vey JK, Lei LS, Camacho L, Wodal W, Kerschbaum A, Segura E, Vandamme E, Gavit P, Ehrlich HJ, Barrett PN, Baker DA, Transfusion 2012 52 803 809 21981280
12. A new liquid intravenous immunoglobulin with three dedicated virus reduction steps: virus and prion reduction capacity. Poelsler G, Berting A, Kindermann J, Spruth M, Hammerle T, Teschner W, Schwarz HP, Kreil TR, Vox Sang 2008 94 184 192 10.1111/j.1423-0410.2007.01016.x 18167162 (Pubitemid 351379655)
13. A new liquid, intravenous immunoglobulin product (IGIV 10%) highly purified by a state-of-the-art process. Teschner W, Butterweck HA, Auer W, Muchitsch EM, Weber A, Liu SL, Wah PS, Schwarz HP, Vox Sang 2007 92 42 55 10.1111/j.1423-0410.2006.00846.x 17181590 (Pubitemid 44950349)
14. A vero cell-derived whole-virus H5N1 vaccine effectively induces neuraminidase-inhibiting antibodies. Fritz R, Sabarth N, Kiermayr S, Hohenadl C, Howard MK, Ilk R, Kistner O, Ehrlich HJ, Barrett PN, Kreil TR, J Infect Dis 2012 205 28 34 10.1093/infdis/jir711 22090447
15. A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models. Kistner O, Crowe BA, Wodal W, Kerschbaum A, Savidis-Dacho H, Sabarth N, Falkner FG, Mayerhofer I, Mundt W, Reiter M, Grillberger L, Tauer C, Graninger M, Sachslehner A, Schwendinger M, Bruhl P, Kreil TR, Ehrlich HJ, Barrett PN, PLoS One 2010 5 9349 10.1371/journal.pone.0009349 20186321
16. Seroprevalence to influenza A(H1N1) 2009 virus-where are we? Broberg E, Nicoll A, Mato-Gauci A, Clin Vaccine Immunol 2011 18 1205 1212 10.1128/CVI.05072-11 21653743
17. A contributing role for anti-neuraminidase antibodies on immunity to pandemic H1N1 2009 influenza A virus. Marcelin G, DuBois R, Rubrum A, Russell CJ, McElhaney JE, Webby RJ, PLoS One 2011 6 26335 10.1371/journal.pone.0026335 22039464
18. Pathogenesis of pandemic influenza A (H1N1) and triple-reassortant swine influenza A (H1) viruses in mice. Belser JA, Wadford DA, Pappas C, Gustin KM, Maines TR, Pearce MB, Zeng H, Swayne DE, Pantin-Jackwood M, Katz JM, Tumpey TM, J Virol 2010 84 4194 4203 10.1128/JVI.02742-09 20181710
19. Limited susceptibility of chickens, turkeys, and mice to pandemic (H1N1) 2009 virus. Kalthoff D, Grund C, Harder TC, Lange E, Vahlenkamp TW, Mettenleiter TC, Beer M, Emerg Infect Dis 2010 16 703 705 10.3201/eid1604.091491 20350393
20. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Li GM, Chiu C, Wrammert J, McCausland M, Andrews SF, Zheng NY, Lee JH, Huang M, Qu X, Edupuganti S, Mulligan M, Das SR, Yewdell JW, Mehta AK, Wilson PC, Ahmed R, Proc Natl Acad Sci U S A 2012 109 9047 9052 10.1073/pnas.1118979109 22615367
21. - 1976 and, H1N1 influenza virus vaccines boost anti-hemagglutinin stalk antibodies in humans. Miller MS, Tsibane T, Krammer F, Hai R, Rahmat S, Basler CF, Palese P, J Infect Dis 2009 2013 207 98 105
22. Boosting heterosubtypic neutralization antibodies in recipients of 2009 pandemic H1N1 influenza vaccine. Qiu C, Huang Y, Wang Q, Tian D, Zhang W, Hu Y, Yuan Z, Zhang X, Xu J, Clin Infect Dis 2012 54 17 24 10.1093/cid/cir753 22052887
23. B cell response and hemagglutinin stalk-reactive antibody production in different age cohorts following 2009 H1N1 influenza virus vaccination. Sangster MY, Baer J, Santiago FW, Fitzgerald T, Ilyushina NA, Sundararajan A, Henn AD, Krammer F, Yang H, Luke CJ, Zand MS, Wright PF, Treanor JJ, Topham DJ, Subbarao K, Clin Vaccine Immunol 2009 2013 20 867 876
24. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. Wrammert J, Koutsonanos D, Li GM, Edupuganti S, Sui J, Morrissey M, McCausland M, Skountzou I, Hornig M, Lipkin WI, Mehta A, Razavi B, Del RC, Zheng NY, Lee JH, Huang M, Ali Z, Kaur K, Andrews S, Amara RR, Wang Y, Das SR, O'Donnell CD, Yewdell JW, Subbarao K, Marasco WA, Mulligan MJ, Compans R, Ahmed R, Wilson PC, J Exp Med 2011 208 181 193 10.1084/jem.20101352 21220454